Mississippi, New Hampshire, and Oklahoma were the top three leading U.S states by number of deaths due to asthma per 100,000 population as of 2022. Mississippi reported 1.6 deaths per 100,000 population with asthma as the underlying cause of death. In 2021, around 40 percent of people in the United States with asthma reported experiencing an asthma episode in the past 12 months. Prevalence As of 2022, around eight percent of individuals in the United States were reported to currently have asthma. New Hampshire and Rhode Island were the leading states by lifetime prevalence of asthma among adults in 2021. Furthermore, Rhode Island and Maine have the highest current prevalence of asthma among adults in the United States. Treatment Asthma is a chronic disease that affects the airways of the lungs, and can cause shortness of breath, tightness or pain in the chest, coughing, and wheezing. Asthma symptoms can be treated through corticosteroid inhalers, such as albuterol. The number of albuterol prescriptions in the United States was around 59 million in 2022. The current out-of-pocket cost for albuterol is eight U.S. dollars.

In 2022, the number of deaths from asthma in Spain amounted to *** cases, up from *** deaths reported a year prior. These figures were fluctuating within the period analyzed, with the lowest value reached in 2006 and the highest in 2015. Asthma is a chronic disease that affects the lungs. Common symptoms of this inflammatory condition include difficulty breathing, and coughing episodes, among others.

In 2022, around 8.2 percent of the U.S. population currently had asthma. Over the past couple decades, the share of the U.S. population with current asthma has fluctuated. The years 2010 and 2011 saw the highest prevalence rates, with 8.5 percent in both years.

Asthma Asthma is a complicated chronic illness that affects a person’s ability to breathe. Symptoms include shortness of breath, wheezing and coughing. Asthma is treatable through avoidance of triggers and through inhaled corticosteroids (an inhaler). Prescriptions of Albuterol, a commonly prescribed inhaler, have increased significantly in the United States. Fortunately, in recent years, the out-of-pocket costs of albuterol have decreased. Asthma among the states The prevalence of asthma in U.S. states varies, with Rhode Island, Maine, and New Hampshire reporting the highest current rates of asthma. However, despite having the highest prevalence rates, these states do not have the highest death rates due to asthma. As of 2021, Mississippi and Hawaii had the highest death rates from asthma in the United States. Among all U.S. residents, the prevalence of active asthma attacks within the past 12 months has decreased over the last few years.

Around 7.7% of Americans have asthma, including 20.2 million adults and 4.6 million children. This study examines asthma mortality trends and disparities across U.S. demographic and geographic groups from 1999 to 2020. A retrospective analysis was conducted using the CDC WONDER database to examine asthma-related deaths in the U.S. from 1999 to 2020. Age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 were calculated. Trends and annual percent changes (APCs) were assessed overall and stratified by sex, race, region, and age. From 1999 to 2020, the U.S. recorded 221 161 asthma-related deaths (AAMR: 3.07), mostly in medical facilities. Mortality declined from 1999 to 2018 (APC: −1.53%) but surged from 2018 to 2020 (APC: 28.63%). Females, NH Blacks, and NH American Indians had the highest mortality rates. Older adults (≥65) had the greatest burden, with younger groups showing notable increases post-2018. Rural areas and the West reported slightly higher rates than urban and other regions. Hawaii and the District of Columbia had the highest AAMRs, while Florida and Nevada had the lowest. Asthma-related mortality in the U.S. declined until 2018 but sharply increased from 2018 to 2020, with rises across all demographic groups, regions, and settings. Females, NH Blacks, and older adults consistently had higher mortality rates, while younger age groups showed recent alarming increases. Targeted interventions are urgently needed to address inequities and recent mortality surges.

As of 2021, the states with the highest lifetime prevalence of asthma among adults included New Hampshire, Rhode Island, and Vermont. In New Hampshire and Rhode Island around 17.4 percent of adults self-reported that a doctor, nurse, or other health professional had told them that you had asthma at some pinot in their lifetime. Asthma is a chronic disease affecting the airways of the lungs that can be mild or severe and can cause shortness of breath, tightness or pain in the chest, coughing, and wheezing.

The prevalence of asthma in the United States Asthma in the United States is more common among men than women, with around 8.9 percent of women with current asthma in 2021, compared to 6.5 percent of men. Current asthma is also more common among adults than children, with those aged four years and below the least likely age group to suffer from the disease. It is unclear what exactly causes asthma; however it is believed that both environmental and genetic factors play a role. In 2021, non-Hispanic Blacks were more likely to report currently suffering from asthma than their non-Hispanic white and Hispanic counterparts.

Death from asthma Medicine for asthma can help control the disease in the long-term and provide short-term relief from symptoms. Therefore, deaths from asthma in the United States are rare, with it being the underlying cause of death in about one out of every 100,000 population. The states with the highest death rates from asthma are Mississippi, Hawaii, and Oregon. In 2020, there were a total of 4,145 deaths due to asthma in the United States.

BackgroundThe advanced lung cancer inflammation index (ALI), which reflects both inflammation and nutritional status, has an uncertain role in predicting outcomes for asthma patients. This study aimed to evaluate the association between ALI and mortality from all causes, as well as specific causes including cardiovascular disease (CVD) and cancer-related mortality, among individuals with asthma.MethodsWe analyzed data from 4,829 asthma patients who participated in the U.S. National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Cox proportional hazards models were used to assess the relationship between ALI and both all-cause and cause-specific mortality, adjusting for demographic and clinical variables. Additionally, restricted cubic spline models were applied to explore potential nonlinear trends, while segmented Cox models were used to identify threshold effects. A competing risk model further examined the independent association of ALI with CVD mortality.ResultsOver a median follow-up of 7.83 years, a total of 582 deaths from all causes, 151 cardiovascular-related deaths, and 125 cancer-related deaths were recorded. An L-shaped association was observed between ALI and both all-cause and CVD mortality, with thresholds identified at 82.02 for all-cause mortality and 58.40 for CVD mortality. Compared to the lowest quartile of ALI (Q1), patients in the highest quartile (Q4) had a 49% lower risk of all-cause mortality (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.40–0.66) and a 51% reduction in CVD mortality (HR 0.49, 95% CI 0.29–0.83). This protective effect was further confirmed by the competing risk model. No significant association between ALI and cancer mortality was observed (HR 1.01, 95% CI 0.98–1.03).ConclusionALI was significantly and inversely associated with all-cause and CVD mortality in asthma patients, particularly when ALI values were below 82.02 and 58.40, respectively, where the risk of mortality was substantially lower. These findings suggest that ALI may have clinical utility in assessing prognosis for asthma patients, especially in terms of cardiovascular risk evaluation.

This statistic displays the share of patients who reported asthma symptoms in the past four weeks in Europe in 2016. A higher proportion of patients in the UK reported experiencing daytime and nighttime symptoms of asthma, at 48 and 24 percent respectively.

Overview

New York, NY – May 05, 2025 – Global Asthma Drugs Market size is expected to be worth around USD 45.0 Billion by 2033 from USD 26.4 Billion in 2023, growing at a CAGR of 5.5% during the forecast period from 2024 to 2033.

The global asthma drugs market is witnessing steady growth, driven by the increasing prevalence of asthma and rising awareness of respiratory health. According to the World Health Organization (WHO), asthma affects over 262 million people globally and causes more than 450,000 deaths annually. This has led to growing demand for effective treatment options that can manage symptoms and reduce the risk of severe attacks.

Asthma drugs are primarily classified into two categories: long-term control medications and quick-relief (rescue) medications. Long-term control drugs, such as inhaled corticosteroids and leukotriene modifiers, are prescribed to manage chronic symptoms, while rescue medications, like short-acting beta agonists (SABAs), are used to provide immediate relief during acute episodes.

Biologics are emerging as a major innovation in asthma treatment, particularly for patients with severe eosinophilic asthma that does not respond to standard therapies. Drugs such as omalizumab, mepolizumab, and benralizumab have shown significant efficacy in reducing hospitalizations and improving quality of life.

North America currently leads the asthma drugs market, supported by advanced healthcare systems, high diagnosis rates, and increased access to biologics. However, regions such as Asia-Pacific are expected to grow rapidly due to urbanization, rising air pollution levels, and improved healthcare infrastructure. The market is poised for further expansion as pharmaceutical companies continue to develop targeted therapies and combination inhalers that improve patient outcomes.

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone. ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.

Emergency Drug Kits Market Outlook

The global Emergency Drug Kits market size was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.4 billion by 2032, growing at a CAGR of 7.5% during the forecast period. This growth is largely driven by the increasing incidence of chronic diseases, rising awareness about emergency preparedness, and advancements in medical technology. The need for immediate medical response in life-threatening conditions is also propelling the demand for emergency drug kits across various healthcare settings.

One of the major growth factors in the Emergency Drug Kits market is the increasing prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and severe allergies that require immediate medical intervention. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year. This alarming statistic underscores the necessity for cardiac emergency kits, which are essential in providing timely treatment and potentially saving lives. Additionally, the growing number of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) further augments the need for respiratory emergency kits.

Technological advancements in the medical field are another critical driver of the Emergency Drug Kits market. Innovations in drug formulation and delivery systems have led to the development of more effective and user-friendly emergency drug kits. For instance, auto-injectors for anaphylaxis and pre-filled syringes for cardiac episodes are becoming increasingly popular due to their ease of use, even by non-medical personnel. These advancements not only enhance the efficacy of emergency treatments but also broaden the scope of their application, thereby expanding the market.

Increasing awareness about emergency preparedness among the general population and healthcare providers is also contributing significantly to market growth. Government initiatives and educational campaigns aimed at improving emergency response capabilities are encouraging the adoption of emergency drug kits. For example, various public health organizations provide guidelines and training programs on the proper use of these kits, thereby fostering a culture of preparedness. This heightened awareness is particularly evident in regions prone to natural disasters and other emergencies, where having readily accessible emergency drug kits can be a matter of life and death.

The regional outlook indicates that North America holds the largest share of the Emergency Drug Kits market, driven by advanced healthcare infrastructure, high awareness levels, and significant investment in healthcare facilities. Europe follows closely, with substantial growth anticipated due to increasing chronic disease prevalence and government initiatives promoting emergency preparedness. The Asia Pacific region is expected to witness the highest growth rate, attributed to rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about the benefits of emergency drug kits. Latin America and the Middle East & Africa are also poised for growth, albeit at a slower pace, due to improving healthcare facilities and increasing government initiatives.

Product Type Analysis

The Emergency Drug Kits market can be segmented by product type into Cardiac Emergency Kits, Respiratory Emergency Kits, Anaphylaxis Emergency Kits, and Others. Cardiac emergency kits are designed to provide immediate treatment for heart-related emergencies, such as heart attacks and cardiac arrest. These kits typically contain medications like aspirin, nitroglycerin, and epinephrine, which can help stabilize the patient until further medical assistance is available. The increasing prevalence of cardiovascular diseases globally is driving the demand for these kits, making them a crucial component of the market.

Respiratory emergency kits focus on providing immediate relief for respiratory conditions like asthma attacks, COPD exacerbations, and acute allergic reactions. These kits usually contain bronchodilators, corticosteroids, and oxygen supplies. The rising incidence of respiratory disorders, particularly in urban areas with high pollution levels, is significantly boosting the demand for respiratory emergency kits. Additionally, the prevalence of respiratory conditions among the elderly population further amplifies this demand, making it an essential market segment.

Anaphylaxis emergency kits are specifically designed to t

BackgroundChronic Obstructive Pulmonary Disease (COPD), mainly caused by cigarette smoking, is one of the leading causes of death in the United States (US) and frequent asthma attacks are often exacerbated by cigarette use. Electronic cigarettes (e-cigarettes) are often used to quit cigarette smoking. Prevalence of COPD, asthma, cigarette use, and e-cigarette use differs between racial/ethnic groups. The overall objective was to assess the associations between e-cigarette use and COPD and asthma and how race/ethnicity and cigarette smoking modifies these associations.MethodsData were retrieved from the 2016–2018 and 2020–2021 Behavioral Risk Factor Surveillance System datasets, a national annual health survey representing the US general adult population. Frequency and weighted percentages or means and standard deviations were obtained. Rao-Scott Chi-square test, two-sample t tests, and logistic regression were used to evaluate binary associations between current e-cigarette use and lifetime diagnosis of COPD and asthma. Multivariable analyses using logistic regression were conducted to assess associations between variables. Interaction effects between e-cigarette use and race/ethnicity were assessed and stratified analyses were performed as indicated. All multivariate analyses were stratified by cigarette smoking status.ResultsPrevalence of e-cigarette use was 5.1%, COPD was 6.7%, and asthma was 9.2%. Individuals who currently smoked cigarettes among all racial/ethnic groups, excluding non-Hispanic (NH) American Indian/Alaska Native individuals, were more likely to report current asthma if using e-cigarettes compared to non-use (p 

This statistic displays the prevalence of asthma in selected European countries in 2015. The United Kingdom (UK) had the highest number of individuals with asthma in Europe, with a prevalence of 4.67 million individuals. The number of individuals with asthma in Spain was noticeably less at 1.58 million. The United Kingdom also had the largest share of individuals who self-reported their asthma at 9.4 percent.

Asthma is characterised as a chronic lung condition that often starts in early childhood. It is caused by inflammation of the air tract thereby narrowing the air passages. The severity of symptoms varies between individuals, with the main symptoms including wheezing, breathlessness, a tight chest and coughing. While there is no cure for asthma, there are treatments available which help to control the symptoms. Individuals are issued with controlled medication such as inhalers. The use of such inhalers depends on the individuals treatment plan and how often they need to use the them. According to a survey conducted in Europe 54 percent of individuals in Germany and 52 percent of individuals in the UK use their controller medication every day.

The purpose of this data package is to offer relevant demographic data for those interested to understand the health status of California population groups. This includes health indicators like newborn screenings for congenital diseases, emergency department diagnosis and visits for an asthma attack, infections among California population and surgical site infections along with demographic indicators influenced directly by the population health.

Characteristics of the source population in 2013 across the WIMD 2011 quintiles.

As the world becomes increasingly urbanized, growing populations are exposed to poor ambient air quality and at risk of the associated health outcomes. Urban air quality is affected both by local sources of air pollution and sources outside city borders. Policy-makers who develop air quality policies need to know whether it is most effective to focus on local policies or to spend resources fostering larger regional air quality management cooperation. Identifying the fraction of air pollution exposure from emissions as a function of distance from the city is a critical element of air quality management design. We estimate the health burden associated with exposure to fine particulate matter (PM2.5), ozone (O3), and nitrogen dioxide (NO2) from county-level anthropogenic sources in and around 14 US cities; this analysis is a test-bed to conduct future global analyses. We use adjoint sensitivities calculated from the chemical transport model GEOS-Chem, high resolution satellite-derived surface concentrations of PM2.5 and NO2, and health impact assessment methods. For the 70.2 million people living in these cities, we estimate that 27,740 PM2.5- and O3-related premature deaths and 126,600 NO2-related new asthma cases were attributable to air pollution exposure in 2011. Development within the GEOS-Chem adjoint framework enables sectoral attribution and policy analysis in addition to the rote assessment of impact. We find that 70% of deaths and nearly 100% of these asthma cases were attributable to anthropogenic emissions. There is great variability in the sources of the anthropogenically-related health impacts; within-urban emissions make up 5% in Austin to 56% in Los Angeles and Phoenix (median: 31%) of urban premature deaths and 18% in Austin to 82% in Los Angeles (median: 59.5%) of new asthma cases, with the remaining portions attributable to emissions from outside the urban area. For each city, we estimate the air quality related health benefits associated with the adoption of a vehicle-miles-traveled fee in that city and in multiple spatial regions surrounding the city. The findings suggest that the proportion of urban air pollution that is regional is greater for premature deaths than new asthma cases and for the eastern US than the western US.

This data collection provides information on individuals born in Denmark in 1905 and who were still living in Denmark in 1998. The overall goal of the study was to establish a genetic-epidemiological database to shed light on the aging process among the extremely old. The data focus on their physical and cognitive functioning. Respondents were asked if they had been previously diagnosed with diseases such as diabetes, arthritis, asthma, migraine, cancer, stroke, heart attack, or depression, and if they were experiencing such ailments as cough, body pains, and bone fracture and were taking medication for them. Questions probed respondents' feelings about their health, life, and future. To assess respondents' general health and functioning, they were asked if they needed assistance with toileting, bathing, dressing, and mobility around the house; how often they needed to use the bathroom during the night; and if they used physical aids such as wheelchairs, eyeglasses, crutches, catheters, or diapers. They were also tested for memory and cognition, mobility, vision, speech, hearing, and lung functioning. Information was also elicited on respondents' mental state and awareness, energy level, menopause, frequency of visits with children and family, visits from a nurse, use of home care services, sleeping patterns, smoking and drinking habits, weight gain or loss, exercises, social activities, hobbies, reading habits, television viewing, and recent deaths in the family. Demographic information includes age, education, and marital status.

Between the years 2013 and 2016, more than a third of U.S. youths aged 3 to 17 years had been exposed to secondhand smoke. Secondhand smoke exposure can cause severe and fatal health problems such as respiratory and ear infections, asthma attacks, infant death syndrome.

Introduction: Despite the increasing evidence supporting the use of biologics for treating severe asthma, there is a lack of evidence regarding their use in pregnant women. This study aims to evaluate the safety of biologics for pregnant women, utilizing global pharmacovigilance database. Methods: Reports documented between 1980 and 2023 were extracted from the VigiBase that mentioned pregnancy- or fetus-related reactions with drugs indicated for asthma, including reslizumab, omalizumab, mepolizumab, dupilumab, benralizumab, and other non-biologics. A disproportionality analysis of case–non-case was conducted by calculating the reporting odds ratio (ROR) with 95% confidence interval (95% CI) of adverse maternal, fetal, and newborn outcomes associated with exposure to biologics compared with outcomes associated with other non-biologic asthma medications. Results: A total of 15,715 pregnancy-related reports were analyzed. Reslizumab showed an overall lower reporting frequency of adverse events (ROR, 0.19; 95% CI, 0.05–0.67). Omalizumab (ROR, 3.88; 95% CI, 3.16–4.77), mepolizumab (ROR, 1.87; 95% CI, 1.05–3.36), and dupilumab (ROR, 5.34; 95% CI, 3.90–7.32) commonly showed higher frequencies of spontaneous fetal death. However, these three drugs also had lower frequencies of pregnancy and delivery complications, including preterm birth (omalizumab: ROR, 0.22; 95% CI, 0.16–0.31; mepolizumab: ROR, 0.10; 95% CI, 0.03–0.34; dupilumab: ROR, 0.07; 95% CI, 0.03–0.17), which are outcomes related to late pregnancy. In contrast, benralizumab (ROR, 0.69; 95% CI, 0.48–0.99) differed from the other biologics by showing lower frequencies of spontaneous fetal death (ROR, 0.69; 95% CI, 0.48–0.99) and spontaneous abortion (ROR, 0.47; 95% CI, 0.29–0.78) but higher frequencies of delivery complications (ROR, 1.32; 95% CI, 1.02–1.72), including preterm birth (ROR, 1.46; 95% CI, 1.14–1.86). Conclusions: This global case–non-case study underscores the critical need for further well-designed research to investigate these over-reported outcomes and emphasizes the importance of more rigorous monitoring efforts for these adverse events.

ABSTRACT OBJECTIVE To analyze the impact of two interventions (implementation and suspension of mandatory vehicle inspection) on morbidity and mortality due to conditions related to air pollution, from 2008 to 2017. METHODS Interrupted time series (ARIMA models), using data available in public repositories. RESULTS A total of 229,337 children of up to 5 years old were hospitalized due to respiratory diseases, and 1,053 died (average monthly mortality ratio for this population: 1.12/100,000). Exact 137,876 individuals over 40 years old were hospitalized for an acute myocardial infarction, and 19,492 died (3.7/100,000). A total of 11,010 individuals over 40 years old were hospitalized with malignant neoplasms of the respiratory system; 2,898 died (0.5/100,000). A total of 20,807 individuals over 60 years old were hospitalized with chronic obstructive pulmonary diseases; 2,627 died (1.5/100,000). As for strokes, 69,180 individuals were hospitalized, and 10,866 died (2.1/100,000). We found no significant regression coefficient for the implementation or suspension of the program regarding hospitalizations and deaths. 38,207 children of up to 14 years old were hospitalized with asthma, and 25 of them died (0.007/100,000). The coefficients show a monthly increase of 0.05 deaths/100,000 people (p = 0.01) in the post-inspection period. We found no correlation between the measured concentrations of the pollutants PM2.5 and CO – in a monitoring station, in the central region of the municipality – and the implementation or suspension of the inspection. CONCLUSIONS No evidence confirms that the program had a measurable beneficial impact on morbidity and mortality due to respiratory and circulatory diseases.

Background and aimsPilgrims with pre-existing Chronic Diseases are at high risk of physical stress that can lead to unexpected health outcomes, including multiple visits to the hospital, organ failure, or even death. In addition, the risk of mortality related to Chronic Diseases increases during mass gatherings due to these same reasons. Therefore, this study aims to evaluate the Prevalence of Chronic Diseases and clinical symptoms among pilgrims during Hajj 2024 in Saudi Arabia.MethodsDuring the 2024 Hajj rituals, cross-sectional questionnaires were administered to pilgrims at the Jeddah International Airport. The questionnaire contained questions on sociodemographic information, the presence of Chronic Diseases, types of Chronic Diseases, and clinical symptoms.ResultsA total of 1920 pilgrims were included in the study, with a mean age of 52.03 ± 13.43 and a median of 53 years. Among those, 49.4% were males. The prevalence of Chronic Diseases (CDs) was 36.3% (n = 697). Among those, 16% (n = 308) of them reported hypertension, followed by diabetes 11.6% (n = 222), asthma (4%, n = 76), and cardiovascular diseases (3.4% n = 65). The most common symptoms associated with Chronic Diseases were cough (36.5%, n = 700), followed by fever (21.8%, n = 419), and sore throat (21.2%, n = 407). The presence of diabetes was significantly associated with gender (p = 0.019), while hypertension was more common among male pilgrims (n = 829) compared to female pilgrims (n = 783) (p = 001). Furthermore, the presence of coughing was significantly associated with the age and educational level of the pilgrims (p = 0.001). On the other hand, headaches were more common among females compared to male pilgrims (p = 0.001).ConclusionA considerable number of pilgrims suffer from Chronic Diseases, with hypertension being most common. Further interventions, such as education and management before Hajj, are recommended.